Drug Trial Radar · NCT03793478
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Aug 15, 2018
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Innovative Therapies For Children with Cancer Consortium; Children's Oncology Group
- First posted
- Jan 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
Conditions
- Acute Myeloid Leukemia
Interventions
QuizartinibDrug
Administered orally once daily starting on Day 6 and continuing through Day 28; Optional low intensity consolidation with chemotherapy: Administered orally once daily starting on Day 1 and continuing through Day 28
FludarabineDrug
30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
CytarabineDrug
2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care); Optional high intensity consolidation with chemotherapy and quizartinib: 500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4; Optional low intensity consolidation with chemotherapy: 75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18
Intrathecal (IT) triple chemotherapy prophylaxisDrug
IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
EtoposideDrug
Optional high intensity consolidation with chemotherapy and quizartinib: 100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of dose-limiting toxicities (Phase 1)Time frame: Re-induction Cycle 1 Day 1 up to Day 28 (each cycle is 28 days)
- Composite complete remission (CRc) rate among participants with acute myeloid leukemia (AML) (Phase 1 and 2)Time frame: within 8 years, 8 months
- Pharmacokinetic parameter area under the concentration curve for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)
- Pharmacokinetic parameter apparent clearance (CL/F) for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)
- Pharmacokinetic parameter apparent volume of distribution (Vz/F) for quizartinib and AC886 (Phase 1 and 2)Time frame: Re-induction Phase 1 and 2,Cycle 1: Days 6, 20:Predose, 1 hour (Phase 1 only), 2, 4, and 6 hours; Days 7 and 21:24 hours; Phase 1 and 2 Cycle 2: Days 6 and 20:predose, 3 hours; Continuation Cycle 1 Days 1 and 15:predose, 2-4 hours (each cycle, 28 days)
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
Loma Linda University Cancer Center
Loma Linda, California
University of California, San Francisco
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
A.I. duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
Children's Healthcare of Atlanta
Atlanta, Georgia
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
The University of Texas Southwestern Medical Center Children's Health
Dallas, Texas
Seattle Children's Hospital
Seattle, Washington
Universitair Ziekenhuis Gent
Ghent, Belgium
British Columbia Children's Hospital
Vancouver, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Rigshospitalet
Copenhagen, Denmark
Centre Léon Bérard
Lyon, France
Hôpital Armand-Trousseau
Paris, France
Hôpital des Enfants
Toulouse, France
Rambam Medical Center
Haifa, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Italy
Ospedale Infantile Regina Margherita
Torino, Italy
Prinses Maxima Centrum voor Kinderoncologie
Utrecht, Netherlands
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Sahlgrenska Universitetssjukhuset - Drottning Silvias Barn- och Ungdomssjukhus
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.